TherapeuticsMD Q1 net loss narrows to $2.3M from $17.9M; continuing ops loss $0.24/share

TherapeuticsMD, Inc.

2023-Q1 EPS reported -$0.37 vs consensus $0.06 ▼ miss (-704.6%)

Net loss from continuing operations $2.3M ($0.24/share) vs $17.9M ($2.08) in Q1 2022.
License and service revenues $0.4M, down from $0.7M due to transition to royalty-based business.
Total operating expenses fell 82.8% to $3.1M, reflecting business transformation and reduced infrastructure.
Net loss from discontinued ops $1.3M ($0.13/share) vs $31.1M ($3.62), as wind-down continues.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TherapeuticsMD, Inc. reported first quarter ended March 31, 2023 results: revenue $0.4 million, net income $2.3 million, EPS $0.24 per basic and diluted common share.

Period: first quarter ended March 31, 2023
Revenue: $0.4 million
Net income: $2.3 million
EPS: $0.24 per basic and diluted common share
Result: reported results

Exact text from the filing

Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations of $17.9 million, or $2.08 per basic and diluted common share, for the comparable period in 2022. License and Service Revenues from Continuing Operations • License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended March 31, 2023, compared to $0.7 million in license and service revenue related to sales to other licensees for the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-145019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.